EBMT 2023 | The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks, MBBS, PhD, FRACP, FRCPath, University Hospitals Bristol NHS Trust, Bristol, UK, comments on the potential of treating patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with a chemotherapy-free induction approach consisting of blinatumomab and tyrosine kinase inhibitor (TKI). Prof. Marks explains that this treatment has been shown to induce high measurable residual disease (MRD)-negativity rates in patients and may allow patients to avoid allogeneic stem cell transplantation (alloSCT). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Pfizer, Kite
